Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11515116 | 0.79 | CES2 (0.31) | CES2LPAR1LPAR3 | |
| SCHEMBL18023449 | 0.76 | CES2 (0.32) | CES2 | |
| SCHEMBL7183331 | 0.75 | FDPS (0.36) | TSHRALDH1A1PTGS1PPARGOPRK1 | |
| SCHEMBL11616660 | 0.72 | CES2 (0.31) | CES2LPAR1LPAR3 | |
| SCHEMBL21938390 | 0.72 | CES2 (0.32) | TSHRCES2LPAR1LPAR3 | |
| SCHEMBL15570719 | 0.72 | ABCG2 (0.33) | TSHRALDH1A1PTGS1PPARGOPRK1 | |
| SCHEMBL24726826 | 0.71 | ABCG2 (0.34) | TSHRALDH1A1PTGS1PPARGOPRK1 | |
| SCHEMBL24248160 | 0.70 | CES2 (0.32) | CES2LPAR1LPAR3 | |
| SCHEMBL5753516 | 0.70 | LMNA (0.33) | ALDH1A1CES2LPAR1LPAR3 | |
| SCHEMBL31417821 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10100028-B2 | Synthesis routes for prostaglandins and prostaglandin intermediates using metathesis | PATHEON API SERVICES INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20160237056-A1 | NOVEL SYNTHESIS ROUTES FOR PROSTAGLANDINS AND PROSTAGLANDIN INTERMEDIATES USING METATHESIS | PATHEON API SERVICES INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160237056-A1 | NOVEL SYNTHESIS ROUTES FOR PROSTAGLANDINS AND PROSTAGLANDIN INTERMEDIATES USING METATHESIS | PATHEON API SERVICES INC. | 2016-08-18 | — | — | US | disclosed |
| WO-2015048736-A1 | NOVEL SYNTHESIS ROUTES FOR PROSTAGLANDINS AND PROSTAGLANDIN INTERMEDIATES USING METATHESIS | IRIX PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015048736-A1 | NOVEL SYNTHESIS ROUTES FOR PROSTAGLANDINS AND PROSTAGLANDIN INTERMEDIATES USING METATHESIS | IRIX PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237056-A1 | NOVEL SYNTHESIS ROUTES FOR PROSTAGLANDINS AND PROSTAGLANDIN INTERMEDIATES USING METATHESIS | PTGES, PTGIS, PTGES2 | TSHR 3459/4885HPGD 15/4885ALDH1A1 1734/4885 |
| US-10100028-B2 | Synthesis routes for prostaglandins and prostaglandin intermediates using metathesis | PTGES, PTGIS, PTGES2 | TSHR 3126/4885HPGD 14/4885ALDH1A1 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.